Besides CV protection, SGLT2 inhibitors have been shown to preserve kidney function, as evidenced by trials like CREDENCE [7], DAPA-CKD [8], and EMPA-KIDNEY [9], indicating their benefits in chronic kidney disease (CKD) patients irrespective of DM status. Here, SLC5A2 is linked to diabetes mellitus.